Company Analysis
Sign in

Metagenomi Therapeutics, Inc. (MGX)

Nasdaq: MGX · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.6
◀ Past 4.4● Present 4.9▶ Future 4.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Metagenomi Therapeutics, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 3 in 2024 and 1 in 2023
Applications published
34
9 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology8
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Metagenomi, Inc. a former name
named as the applicant on its applications, in US
0 granted
34 published
Metagenomi, Inc. a former name
US, as the owner printed on each patent
8 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,710Base editing enzymesBiotechnologyMetagenomi, Inc.
Oct 7, 202512,435,323Enzymes with RUVC domainsBiotechnologyMetagenomi, Inc.
Sep 9, 202512,410,449Endonuclease systemsBiotechnologyMetagenomi, Inc.
Apr 29, 202512,286,654Base editing enzymesBiotechnologyMetagenomi, Inc.
Oct 22, 202412,123,014Class II, type V CRISPR systemsBiotechnologyMetagenomi, Inc.
Jul 2, 202412,024,727Enzymes with RuvC domainsBiotechnologyMetagenomi, Inc.
Apr 2, 202411,946,039Class II, type II CRISPR systemsBiotechnologyMetagenomi, Inc.
Aug 1, 202311,713,471Class II, type V CRISPR systemsBiotechnologyMetagenomi, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 19, 20252025/0197891SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCESBiotechnologyMetagenomi, Inc.
Jun 5, 20252025/0179530FUSION PROTEINSBiotechnologyMetagenomi, Inc.
Jun 5, 20252025/0179484FUSION PROTEINSBiotechnologyMetagenomi, Inc.
Jun 5, 20252025/0179452SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTIDE SEQUENCESBiotechnologyMetagenomi, Inc.
May 22, 20252025/0161491SUPPLEMENTATION OF LIVER ENZYME EXPRESSIONBiotechnologyMetagenomi, Inc.
Mar 6, 20252025/0075233MULTIPLEX EDITING WITH CAS ENZYMESBiotechnologyMetagenomi, Inc.
Feb 20, 20252025/0059568CLASS II, TYPE V CRISPR SYSTEMSBiotechnologyMetagenomi, Inc.
Jan 2, 20252025/0002886ENGINEERED AND CHIMERIC NUCLEASESBiotechnologyMetagenomi, Inc.
Jan 2, 20252025/0002881CLASS II, TYPE V CRISPR SYSTEMSBiotechnologyMetagenomi, Inc.
Dec 12, 20242024/0409962ENDONUCLEASE SYSTEMSBiotechnologyMetagenomi, Inc.
What it applied for, 2024 to 2025: Biotechnology 25.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MGX · research, not advice